CRIS Current Research Information System

MASSARI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.100
EU - Europa 2.291
AS - Asia 725
AF - Africa 156
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.095
IT - Italia 543
GB - Regno Unito 404
SE - Svezia 399
VN - Vietnam 273
DE - Germania 232
CH - Svizzera 211
CN - Cina 207
IN - India 158
IE - Irlanda 145
FI - Finlandia 77
FR - Francia 67
CI - Costa d'Avorio 58
RU - Federazione Russa 55
BG - Bulgaria 54
TG - Togo 48
JO - Giordania 42
ZA - Sudafrica 32
EE - Estonia 28
UA - Ucraina 23
NL - Olanda 16
BE - Belgio 13
NG - Nigeria 13
JP - Giappone 10
PL - Polonia 8
SG - Singapore 7
TR - Turchia 6
HK - Hong Kong 5
PK - Pakistan 5
AT - Austria 4
CA - Canada 4
BD - Bangladesh 3
ES - Italia 3
MY - Malesia 3
EG - Egitto 2
GH - Ghana 2
HU - Ungheria 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
Totale 6.274
Salva come PNG Salva come JPEG
Città #
Fairfield 374
Southend 355
Chandler 311
Ashburn 229
Bern 207
Seattle 169
Woodbridge 159
Wilmington 155
Dublin 145
Houston 133
Cambridge 129
Princeton 127
Dong Ket 122
Bologna 116
Boydton 73
Ann Arbor 69
Helsinki 65
Abidjan 58
Turin 57
Sofia 54
Milan 52
Lomé 48
Amman 42
Beijing 41
New York 38
Redmond 36
Westminster 36
Nanjing 34
Berlin 33
Florence 28
Los Angeles 26
San Diego 25
Redwood City 24
Padova 21
Rome 18
Boardman 16
Falls Church 16
Des Moines 15
Shenyang 14
Abeokuta 13
Bühl 13
Changsha 13
Jinan 13
Brussels 12
Lappeenranta 12
Paris 12
Saint Petersburg 12
Monzuno 11
Arezzo 10
Hangzhou 10
Hebei 10
Olalla 10
Tianjin 10
Norwalk 8
Warsaw 8
Bangalore 7
Taiyuan 7
Amsterdam 6
Bremen 6
Glasgow 6
Kumar 6
Mülheim 6
Telgate 6
Verona 6
Dearborn 5
Frankfurt Am Main 5
Izmir 5
Kilburn 5
Mumbai 5
Nanchang 5
San Polo di Torrile 5
Bari 4
Guangzhou 4
London 4
Medford 4
Moscow 4
Mountain View 4
Pune 4
Rimini 4
Singapore 4
Tokyo 4
Zhengzhou 4
Brescia 3
Cardiff 3
Cesena 3
Columbus 3
Costa Mesa 3
Den Haag 3
Genoa 3
Groningen 3
Kuban 3
Lanzhou 3
Montechiarugolo 3
Montefalco 3
Naples 3
Novosibirsk 3
Prescot 3
Reggio Emilia 3
Sant'Agata Bolognese 3
Santerno 3
Totale 4.036
Salva come PNG Salva come JPEG
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 161
Circulating tumor cells in genitourinary tumors 147
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 138
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 127
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 118
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. 115
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 111
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 111
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? 106
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. 105
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 105
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 104
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives 100
Immune checkpoint inhibitors for metastatic bladder cancer 100
Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice 96
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 95
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 95
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 94
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 93
Sopravvivenza di pazienti con recidiva vaginale di carcinoma endometriale: il ruolo della radioterapia e della chirurgia. 92
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 92
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 91
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 91
Urinary biomarkers for prostate cancer 90
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 89
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 87
The prospect of precision therapy for renal cell carcinoma. 82
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 81
BAP1 in solid tumors 81
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: Where do we stand? 80
The human microbiota and prostate cancer: Friend or foe? 80
Is There a Role for Immunotherapy in Prostate Cancer? 76
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 75
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 71
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer 71
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 68
Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis 66
Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma 63
Expected and non-expected immune-related adverse events detectable by CT 62
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 61
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 61
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 61
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach 59
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 58
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 51
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 51
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 50
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 48
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 47
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 46
Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study 43
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 42
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 41
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 40
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 40
Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions? 40
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 39
null 39
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 39
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 38
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 37
SOX2 and PRAME in the "reprogramming" of seminoma cells 36
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 36
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis 34
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 32
Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers 31
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 31
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis 30
Microbiota and prostate cancer 29
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 29
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 27
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 26
Bone targeting agents in patients with metastatic prostate cancer: State of the art 26
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 25
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 24
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 23
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 22
null 22
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 21
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 21
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 21
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 20
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 20
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 20
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 20
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 20
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 19
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 19
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 18
Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer 17
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 17
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 17
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 17
Cabazitaxel in metastatic prostate cancer 17
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 17
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 16
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 16
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 16
Metabolomic profiling in renal cell carcinoma patients: News and views 15
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 15
Totale 5.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201930 0 0 0 0 0 0 0 0 0 0 0 30
2019/20201.106 134 35 4 60 118 95 142 159 147 91 64 57
2020/2021855 99 45 48 54 31 7 26 36 95 44 29 341
2021/20221.091 46 33 41 81 88 56 41 101 133 47 282 142
2022/20232.575 112 151 59 169 214 460 212 129 388 70 228 383
2023/20241.132 131 171 94 95 84 140 37 93 56 91 73 67
Totale 7.003